Drug Profile

Denosumab biosimilar - Hexal/Sandoz

Alternative Names: denosumab-bbdz; GP-2411; Jubbonti; Wyost

Latest Information Update: 23 Jan 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator HEXAL; Sandoz
Class Antihypercalcaemics; Antineoplastics; Antirheumatics; Calcium regulators; Immunotherapies; Monoclonal antibodies; Osteoporosis therapies
Mechanism of Action Antibody-dependent cell cytotoxicity; RANK ligand inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Registered Bone disorders; Postmenopausal osteoporosis

Most Recent Events

14 Jan 2025 Sandoz anticipates launch of denosumab biosimilar in the US and the European Union in 2025
22 May 2024 Registered for Bone disorders in Iceland (SC)
22 May 2024 Registered for Bone disorders in Liechtenstein (SC)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com